- Company
- Negotiation on the price of Onureg has started
- by Eo, Yun-Ho May 10, 2023 11:17pm
- Suggestion of treatment options for patients unable to undergo hematopoietic stem cell transplantation Onureg, an acute myelogenous leukemia maintenance treatment drug, recently entered into drug price negotiations for insurance coverage. After passing the HIRA Cancer Disease Review Committee in December of last year and the Pharmaceutica
- Company
- Forxiga, has the largest number of clinical trials
- by Jung, Sae-Im May 10, 2023 05:58am
- With the expansion of SGLT-2 inhibitor coverage, which began in April, combination prescriptions of various diabetes drugs and SGLT-2 drugs are expected to increase. However, as the clinical basis for each drug is a prerequisite for the expansion of this benefit, there are differences in detailed application depending on the presence or absence
- Company
- Betmiga generics’ market share rises to 49%...
- by Kim, Jin-Gu May 9, 2023 05:38am
- Generic versions of mirabegron have increased their influence in Korea’s overactive bladder market. The overall market share of the generic products in Q1 was 49%, chasing sales of the original drug, ‘Betmiga,’ right under the nose. In particular, sales of Hanmi Pharmaceuticals ‘Mirabek’ and Chong Kun Dang’s ‘Selebeta’ have shown
- Company
- Ildong’s diabetes combi Qtern registered for reimbursement
- by Kim, Jin-Gu May 8, 2023 05:41am
- Ildong Pharmaceutical announced on the 3rd that its type 2 diabetes combination drug 'Qtern 5/10mg' was registered as an item subject to medical care benefit as of May 1st. As a result, Qtern is covered by insurance as a three-drug therapy drug that can be used in combination with metformin when HbA1c is 7% or higher even if the two-drug the
- Company
- Xospata passed the first hurdle to increasing benefits
- by Eo, Yun-Ho May 8, 2023 05:41am
- After submitting the application for expansion of Xospata's benefits, the Health Insurance Review and Assessment Service's Cancer Disease Review Committee succeeded in setting the reimbursement standard. As a result, attention is focused on future procedures such as the schedule for submission to the Pharmaceutical Reimbursement Evaluation C
- Company
- New polycythemia vera drug Besremi may be prescribed
- by Eo, Yun-Ho May 8, 2023 05:40am
- The Taiwanese pharmaceutical company PharmaEssentia’s first new drug ‘Besremi’ can now be prescribed in general hospitals in Korea. According to industry sources, PharmaEssentia’s polycythemia vera treatment, Besremi (Ropeginterferon alfa-2b) passed drug committee reviews of tertiary hospitals in Korea including Seoul National Unive
- Company
- Merck establishes a bio-production facility in Daejeon
- by Jung, Sae-Im May 8, 2023 05:40am
- Merck Life Sciences establishes a bio raw material production facility in Korea. Merck Lifesciences announced on the 3rd that it has signed a memorandum of understanding (MOU) with the Ministry of Trade, Industry and Energy and Daejeon Metropolitan City to establish a production facility for raw and subsidiary materials used in the new Asia-
- Company
- AbbVie Korea merges with Allergan Korea
- by Jung, Sae-Im May 7, 2023 08:37pm
- AbbVie Korea announced on the 2nd that it will complete the integration of domestic corporations with Allergan Korea on May 1st and launch as a single corporation. The domestic corporation merger is a follow-up to the announcement of the merger and acquisition of Allergan by the global headquarters in May 2020. It plans to integrate the entir
- Company
- BeigeneKR's hematologic cancer drug Brukinsa, covered from M
- by Jung, Sae-Im May 4, 2023 05:50am
- BeigeneKR announced on the 2nd that Brukinsa, a treatment for Waldenstrom's macroglobulinemia (WM), will be covered from this month. Brukinsa reimbursement applies to monotherapy in adult patients with Waldenstrom's macroglobulinemia who have received one or more prior therapies. Brukinsa is a second-generation BTK inhibitor that targets B
- Company
- Erleada can be prescribed at general hospitals in Korea
- by Eo, Yun-Ho May 4, 2023 05:50am
- The new prostate cancer drug ‘Erleada’ can now be prescribed at general hospitals in Korea According to industry sources Janssen Korea’s metastatic hormone-sensitive prostate cancer (mHSPC) treatment Erleada (apalutamide) passed the drug committees (DCs) of tertiary hospitals in Korea including the Seoul National University Hospital an
